Enanta Pharmaceuticals (ENTA) Revenue & Revenue Breakdown
Enanta Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$79.20M
Latest Revenue (Q)
$17.97M
Main Segment (Y)
Royalty
Main Geography (Y)
Royalty
Enanta Pharmaceuticals Revenue by Period
Enanta Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-09-30 | $79.20M | -8.07% |
| 2022-09-30 | $86.16M | -11.24% |
| 2021-09-30 | $97.07M | -20.74% |
| 2020-09-30 | $122.47M | -40.31% |
| 2019-09-30 | $205.20M | -0.69% |
| 2018-09-30 | $206.63M | 100.97% |
| 2017-09-30 | $102.81M | 16.48% |
| 2016-09-30 | $88.27M | -45.13% |
| 2015-09-30 | $160.88M | 236.98% |
| 2014-09-30 | $47.74M | 48.94% |
| 2013-09-30 | $32.05M | -23.15% |
| 2012-09-30 | $41.71M | -0.42% |
| 2011-09-30 | $41.88M | 83.99% |
| 2010-09-30 | $22.76M | - |
Enanta Pharmaceuticals generated $79.20M in revenue during NA 2023, up -8.07% compared to the previous quarter, and up 38.33% compared to the same period a year ago.
Enanta Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $17.97M | 5.38% |
| 2024-03-31 | $17.05M | -5.27% |
| 2023-12-31 | $18.00M | -4.91% |
| 2023-09-30 | $18.93M | 0.21% |
| 2023-06-30 | $18.89M | 6.16% |
| 2023-03-31 | $17.80M | -24.55% |
| 2022-12-31 | $23.59M | 16.09% |
| 2022-09-30 | $20.32M | 4.30% |
| 2022-06-30 | $19.48M | 4.08% |
| 2022-03-31 | $18.72M | -32.31% |
| 2021-12-31 | $27.65M | 17.28% |
| 2021-09-30 | $23.57M | 9.02% |
| 2021-06-30 | $21.62M | 7.41% |
| 2021-03-31 | $20.13M | -36.58% |
| 2020-12-31 | $31.74M | 34.33% |
| 2020-09-30 | $23.63M | 26.69% |
| 2020-06-30 | $18.65M | -32.46% |
| 2020-03-31 | $27.62M | -47.46% |
| 2019-12-31 | $52.57M | 2.45% |
| 2019-09-30 | $51.31M | 15.66% |
| 2019-06-30 | $44.37M | 11.95% |
| 2019-03-31 | $39.63M | -43.29% |
| 2018-12-31 | $69.89M | 3.99% |
| 2018-09-30 | $67.20M | 17.36% |
| 2018-06-30 | $57.26M | 30.00% |
| 2018-03-31 | $44.05M | 15.59% |
| 2017-12-31 | $38.11M | -49.81% |
| 2017-09-30 | $75.93M | 910.88% |
| 2017-06-30 | $7.51M | -16.16% |
| 2017-03-31 | $8.96M | -14.00% |
| 2016-12-31 | $10.42M | -18.88% |
| 2016-09-30 | $12.84M | -8.13% |
| 2016-06-30 | $13.98M | 7.49% |
| 2016-03-31 | $13.00M | -73.16% |
| 2015-12-31 | $48.45M | 236.05% |
| 2015-09-30 | $14.42M | 24.29% |
| 2015-06-30 | $11.60M | -79.78% |
| 2015-03-31 | $57.37M | -25.98% |
| 2014-12-31 | $77.50M | 2838.87% |
| 2014-09-30 | $2.64M | -93.73% |
| 2014-06-30 | $42.05M | 1846.81% |
| 2014-03-31 | $2.16M | 141.88% |
| 2013-12-31 | $893.00K | -33.80% |
| 2013-09-30 | $1.35M | -18.19% |
| 2013-06-30 | $1.65M | 37.88% |
| 2013-03-31 | $1.20M | -95.71% |
| 2012-12-31 | $27.86M | 1399.41% |
| 2012-09-30 | $1.86M | -26.91% |
| 2012-06-30 | $2.54M | -93.05% |
| 2012-03-31 | $36.56M | 4834.55% |
| 2011-12-31 | $741.00K | 100.00% |
| 2011-09-30 | - | - |
Enanta Pharmaceuticals generated $17.97M in revenue during Q3 2024, up 5.38% compared to the previous quarter, and up 100.99% compared to the same period a year ago.
Enanta Pharmaceuticals Revenue Breakdown
Enanta Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Sep 23 | Sep 21 | Sep 20 | Sep 19 | Sep 18 |
|---|---|---|---|---|---|
| Royalty | $78.20M | $97.07M | $122.47M | $205.20M | $191.63M |
| License | $1.00M | - | - | - | - |
| Milestone | - | - | - | - | $15.00M |
Enanta Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Sep 23: Royalty (98.74%), and License (1.26%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalty | $17.05M | $18.00M | $18.93M | $18.89M | $17.80M | $22.59M | $51.31M | $44.37M | $39.63M | $69.89M | $67.20M | $57.26M |
| License | - | - | - | - | - | $1.00M | - | - | - | - | - | - |
| Milestone | - | - | - | - | - | - | - | - | - | - | - | $15.00M |
Enanta Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Royalty (100.00%).
Enanta Pharmaceuticals Revenue Breakdown by Country
Annual Revenue by Country
| Country | Sep 21 | Sep 20 | Sep 19 | Sep 18 |
|---|---|---|---|---|
| Royalty | $97.07M | $122.47M | $205.20M | $191.63M |
| Milestone | - | - | - | $15.00M |
Enanta Pharmaceuticals's latest annual revenue breakdown by geography, as of Sep 21: Royalty (100.00%).
Enanta Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ENTA | Enanta Pharmaceuticals | $79.20M | $17.97M |
| MRUS | Merus | $43.95M | $7.33M |
| HOWL | Werewolf Therapeutics | $19.94M | $742.00K |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| IKNA | Ikena Oncology | $9.16M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| KRON | Kronos Bio | $6.29M | $2.69M |
| CRNX | Crinetics Pharmaceuticals | $4.01M | $640.00K |
| IPSC | Century Therapeutics | $2.23M | $771.00K |
| INBX | Inhibrx | $1.80M | - |
| LYEL | Lyell Immunopharma | $130.00K | $3.00K |
| DSGN | Design Therapeutics | - | - |
| CGEM | Cullinan Oncology | - | - |
| CCCC | C4 Therapeutics | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| EWTX | Edgewise Therapeutics | - | - |
ENTA Revenue FAQ
What is Enanta Pharmaceuticals’s yearly revenue?
Enanta Pharmaceuticals's yearly revenue for 2023 was $79.2M, representing a decrease of -8.07% compared to 2022. The company's yearly revenue for 2022 was $86.16M, representing a decrease of -11.24% compared to 2021. ENTA's yearly revenue for 2021 was $97.07M, representing a decrease of -20.74% compared to 2020.
What is Enanta Pharmaceuticals’s quarterly revenue?
Enanta Pharmaceuticals's quarterly revenue for Q3 2024 was $17.97M, a 5.38% increase from the previous quarter (Q2 2024), and a -4.88% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $17.05M, a -5.27% decrease from the previous quarter (Q1 2024), and a -4.16% decrease year-over-year (Q2 2023). ENTA's quarterly revenue for Q1 2024 was $18M, a -4.91% decrease from the previous quarter (Q4 2023), and a -23.67% decrease year-over-year (Q1 2023).
What is Enanta Pharmaceuticals’s revenue growth rate?
Enanta Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was -18.41%, and for the last 5 years (2019-2023) was -61.40%.
What are Enanta Pharmaceuticals’s revenue streams?
Enanta Pharmaceuticals's revenue streams in p 23 are Royalty, and License. Royalty generated $78.2M in revenue, accounting 98.74% of the company's total revenue, down -19.44% year-over-year. License generated $1M in revenue, accounting 1.26% of the company's total revenue
What is Enanta Pharmaceuticals’s main source of revenue?
For the fiscal year ending Sep 23, the largest source of revenue of Enanta Pharmaceuticals was Royalty. This segment made a revenue of $78.2M, representing 98.74% of the company's total revenue.